DGAP-News

Asklepios Kliniken GmbH: Sustainable growth in first nine months of 2015 - Seite 2

63.8% of sales.

In total, consolidated interim income climbed by 23.0% to EUR 135.1 million
in the first nine months (previous year: EUR 109.8 million). This
corresponds to a return on sales of 5.8% (previous year: 4.9%).

The net cash flow totalled EUR 234.7 million in the first nine months.
Investments amounted to EUR 138.5 million in the reporting period. The
proportion of own funds was 75.2% and thus once again higher than in the
previous year (65.0%).

Successful promissory note placement ensures long-term growth financing

In August 2015, Asklepios Kliniken GmbH successfully placed a promissory
note loan with a volume of EUR 580 million. Due to the high demand, the
issue was many times oversubscribed.

Stephan Leonhard, CFO and Deputy Chairman, emphasises: "The Asklepios Group
thereby concluded one of the largest promissory note issues in the
healthcare sector. The favourable conditions strengthen our earnings power
and secure further financing for the company. With an average term for the
promissory note loan of 8 years, we further optimised the maturity profile
of liabilities."

Following the promissory note placement, total assets increased from EUR
2,863.4 million (31 December 2014) to EUR 3,484.2 million as at 30
September 2015. Equity increased by EUR 140.4 million or 14.0% compared to
31 December 2014 to EUR 1,142.1 million. The debt ratio improved on the
previous year (31 December 2014: 1.8x) to 1.6 times EBITDA. The interest
coverage ratio increased to 10.2 times EBITDA compared to 9.6x in the same
period of the previous year.

Cash and cash equivalents amounted to EUR 606.3 million as at 30 September
2015. Together with the unutilised credit facilities, these ensure a
persistently high level of reserves available at short notice.

Asklepios Kliniken GmbH confirms outlook for year as a whole

On the basis of the positive business development in the first nine months
of 2015, the Group's management is also optimistic for the year as a whole
and is confirming its outlook. The business goals for 2015 include organic
revenue growth in a range of around 2% to 4% and a slight but sustainable
increase in EBIT and EBITDA compared to the previous year.

Asklepios will be publishing its consolidated interim report as at 30
September 2015 today in the Investor Relations section of the Asklepios
website (www.asklepios.com).

About Asklepios:

The healthcare group Asklepios Kliniken GmbH is one of the leading private
operators of hospitals and healthcare facilities in Germany. The clinic
group stands for highly professional care of its patients with a clear
commitment to medical quality, innovation and social responsibility.
Asklepios has been performing dynamically on this basis since it was
founded 30 years ago. The Group currently has around 150 healthcare
facilities throughout Germany and employs more than 45,000 people.
Approximately 2.2 million patients were treated in Asklepios Group
facilities in the 2014 financial year.


IR contact:

Asklepios Kliniken GmbH
Debusweg 3
61462 Königstein-Falkenstein
Tel: [phone]
Fax: [phone]
[e-mail]

www.asklepios.com/ir

Press contact:

Rune Hoffmann
Head of Corporate Communications and Marketing
Tel.: [phone]
Fax: [phone]
[e-mail]


---------------------------------------------------------------------------

26.11.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------


416453 26.11.2015